Mylan's Nebivolol Is "Approvable" At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The beta blocker's user fee date had been extended by three months following submission of additional analysis. Mylan expects the anti-hypertensive to be the cornerstone of its brand division.